Human Oncology & Pathogenesis Program

The Jedd Wolchok Lab

Jedd D. Wolchok, MD, PhD, FASCO

Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program

Professor

The overall goals of my laboratory efforts are to develop and implement new ways to use the immune system to treat cancer.

Some of our ongoing projects include:

Investigation of the GITR pathway as it relates to regulatory and effector T cells.
Use of OX40 agonists alone and in combination with chemotherapy.
Exploration of the role of myeloid derived suppressor cells in tumor immunity.
Studying of the mechanisms underlying coordinated regulation of myeloid cells and IDO in the tumor environment and their therapeutic relevance.
Role of CD47 in T cell signaling.
Developing optimal cancer vaccine strategies in pre-clinical mouse models.
Role of exercise in immune checkpoint blockade.

We are also closely aligned with the Ludwig Center for Cancer Immunity and work closely with that group to monitor immune responses in patients receiving experimental immunotherapy treatments.

Featured News

To Improve Immunotherapy, Researchers Look to Shift Immune Cells’ Access to Sugar

Monday, February 15, 2021

More sugar available for immune cells could mean better immune responses against cancer.

At Work

Working It Out: Does Exercise Boost the Effectiveness of Melanoma Treatment?

Thursday, November 5, 2020

Physician-scientist Allison Betof Warner is studying the effects of exercise on melanoma and other cancers.

Finding

Discovery of Unusual Cell Type Could Help Guide Immunotherapy

Tuesday, June 12, 2018

A newly identified group of immunosuppressive cells could provide insight into the effects of immunotherapy drugs.

View All Featured News

Publications

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol 2021:Jco2102229.

Budhu, S, Giese r, Gupta A, Fitzgerald K, Zappasodi, R, Schad S, Hirschhorn D, Campesato LF, DeHenau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, Merghoub T. Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Rep. 2021 Jan 12;34(2):108620.

Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, Zamarin D, Shi H, Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A, Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD, Rudin CM, Merghoub T. Tim-4(+) cavity-resident macrophages impair anti-tumor CD8(+) T cell immunity. Cancer Cell 2021. May 29:S1535-6108(21)00272-5.

Zappasodi R, Serganova I, Cohen I, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S, Lubin M, Ko M, Mane MM, Zhong H, Liu C, Ghosh A, Abu- Akeel M, Ackerstaff E, Koutcher JA, Ho PC, Delgoffe GM, Blasberg R, Wolchok JD and Merghoub T. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors. Nature 2021 Mar;591(7851):652-658.

Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight 2021;6.

View All Publications

People

Jedd D. Wolchok, MD, PhD, FASCO

Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program

Professor

Physician-scientist Jedd Wolchok investigates novel approaches for cancer immunotherapy and mechanisms of tumor cell–immune cell interactions. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials.
Princeton University, Princeton, NJ BA
New York University, New York, NY MS
New York University, New York, NY PhD
New York University, New York, NY MD

View physician profile: Physician profile

Members

Jedd D. Wolchok, MD, PhD, FASCO — Jedd D. Wolchok
Lab Head

Beatrice Yin, MA — Beatrice Yin
Research Lab Manager

Daniel Hirschhorn-Cymerman, PhD — Daniel Hirschhorn-Cymerman
Senior Research Scientist

Sadna Budhu, PhD — Sadna Budhu
Research Associate

Roberta Zappasodi, PhD — Roberta Zappasodi
PICI Bridge Scholar

Hyejin Choi, PhD — Hyejin Choi
Research Associate

Mathieu Gigoux, PhD — Mathieu Gigoux
Research Fellow

Chien-Huan Weng, PhD — Chien-Huan Weng
Research Fellow

Levi Mark Bala Mangarin, BS — Levi Mark Bala Mangarin
Bioinformatics Technician

Shakuntala Tiwari
Senior Research Assistant

Dmitriy Zamarin, MD, PhD — Dmitriy Zamarin
Assistant Attending Physician

Alexander Lesokhin, MD — Alexander Lesokhin
Assistant Member

Danny Khalil

Medical Oncologist

Bianca Santomasso, MD, PhD — Bianca Santomasso
Neuro-Oncologist

Allison Betof, MD, PhD — Allison Betof
Medical Oncologist

Arnab Ghosh, MBBS, PhD — Arnab Ghosh
Hematologic Oncologist

Andrew Chow, MD, PhD — Andrew Chow
Medical Oncology Fellow

Linda Hamadene
Senior Research Technician

Lab Alumni

Stephanie Terzulli

Immunotherapy Program Manager

David A. Schaer
Senior Research Scientist

Luis Felipe Campesato, PhD — Luis Felipe Campesato
Research Associate

Judith Michels, MD, PhD — Judith Michels
Research Fellow

Feng Zhao

Research Technician

Andre P. Burey

Research Technician

Michael Postow, MD — Michael Postow
Assistant Attending Physician

Margaret K. Callahan, MD, PhD — Margaret K. Callahan
Assistant Attending, Department of Medicine

Claire Friedman, MD — Claire Friedman
Medical Oncologist

Humilidad Gallardo

Research Laboratory Manager

Polly D. Gregor

Assistant Member

Robert Jenq

Research Fellow

Shigehisa Kitano

Visiting Investigator

Jeanie Melson

Administrative Assistant

Zhenyu Mu

Research Assistant

Kelly Piersanti

Research Technician

Rosemarie Ramsawak

Senior Research Technician

Teresa Rasalan

Research Assistant

Sapna Tandon

Senior Research Technician

Shachi Vyas

Senior Research Technician

Leila Sellam
Graduate Research Assistant

Mohamed Amine Feliachi, Research Technician — Mohamed Amine Feliachi
Research Technician

Kelly Fitzgerald
Medical Oncology Fellow

David Redmond, PhD — David Redmond
Bioinformatics Engineer IV

Jacob Ricca

Research Technician

Lab Affiliations

Achievements

The use of immunomodulatory antibodies, specifically antibodies which interfere with the CTLA-4 co-inhibitory pathway has been studied in over a dozen clinical trials. Dr. Wolchok led a phase III study of ipilimumab plus dacarbazine in patients with previously untreated metastatic melanoma. Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (Wolchok et al, NEJM 30;364(26):2517-26, 2011)

Get in Touch

646-888-5178

Clinical Office
646-888-2585| Laboratory Office

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Jedd D. Wolchok discloses the following relationships and financial interests:

Amgen
Provision of Services (uncompensated)
Apricity Health
Ownership / Equity Interests; Provision of Services
Arsenal IO Canada Parent, Inc.
Ownership / Equity Interests; Provision of Services
Ascentage Pharma
Ownership / Equity Interests; Provision of Services
Astellas
Provision of Services (uncompensated)
AstraZeneca
Provision of Services (uncompensated)
BeiGene, Ltd.
Ownership / Equity Interests; Provision of Services
Bicara Therapeutics, Inc.
Provision of Services
Boehringer Ingelheim
Provision of Services (uncompensated)
Bristol-Myers Squibb
Provision of Services
Chugai Pharmaceuticals
Provision of Services (uncompensated)
Daiichi Sankyo
Provision of Services
Dragonfly Therapeutics, Inc.
Provision of Services (uncompensated)
Georgiamune, LLC
Provision of Services (uncompensated)
Idera Pharmaceuticals, Inc.
Provision of Services (uncompensated)

Imvaq Therapeutics
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
Journal of Experimental Medicine
Provision of Services
Linnaeus Therapeutics
Ownership / Equity Interests
Maverick Therapeutics, Inc.
Provision of Services
Merck & Co Inc.
Intellectual Property Rights; Provision of Services (uncompensated)
Merial Limited
Intellectual Property Rights
PsiOxus Therapeutics Ltd
Provision of Services (uncompensated)
Recepta Biopharma S.A.
Provision of Services (uncompensated)
Sellas Life Science Group
Provision of Services
Surface Oncology
Provision of Services
Tizona Therapeutics
Ownership / Equity Interests; Provision of Services
Trieza Pharmaceuticals, Inc.
Ownership / Equity Interests
Trishula Therapeutics, Inc.
Provision of Services
Werewolf Therapeutics, Inc.
Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures